DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

LaunchTrends: Yervoy and Zelboraf (Wave 2) 2012

BioTrends Research Group is pleased to announce a new syndicated report series, LaunchTrends®: Yervoy and Zelboraf. This Three wave primary research study will follow the launch of Bristol-Myers Squibb’s Yervoy and Genentech / Daiichi Sankyo, Inc.’s Zelboraf. Wave 1 tracks the uptake of Yervoy 6 months post-launch and Zelboraf at launch while subsequent waves will be fielded every 6 months to monitor the competitive dynamics of these therapies. LaunchTrends® are syndicated reports that track the trial, adoption and usage of new products from launch through maturity. These report series provide information on how new products fit into the treatment algorithm, impact current therapies, and changing market dynamics. They provide information on awareness, familiarity, and perceived clinical advantages and disadvantages of new products. And, they capture the promotional messages and activities of key market players.

Questions Answered in This Report:

  • Understand awareness of and familiarity with Yervoy and Zelboraf among Medical Oncologists

  • Understand the perceived clinical advantages and disadvantages of Yervoy compared to other marketed agents used in treating Metastatic Melanoma

  • Understand the perceived clinical advantages and disadvantages of Zelboraf compared to other marketed agents used in treating Metastatic Melanoma

  • Understand where Yervoy and Zelboraf are expected to fit in the treatment algorithm for patients with Metastatic Melanoma

  • Track the trial, adoption, and usage trends including anticipated future trends for the treatment of Metastatic Melanoma

  • Collect information on the promotional messages and activities being employed by Bristol-Myers Squibb and Genentech / Daiichi Sankyo Inc.

  • Capture interest and anticipated value of next generation therapies in development


Sample Frame & Methodology:

- This report will include responses from a random sample of 100 Medical Oncologists

- A qualitative follow up arm includes telephone interviews conducted with a sub-set of 15 survey respondents

To qualify for participation, Medical Oncologists must meet the following criteria:

- In practice between 2 and 30 years

- Minimum of 50 patients with Melanoma personally treated over the last year

- More than 50% of time spent in clinical practice


- Final report in powerpoint format (from each wave)

- Complete set of frequency tables, summary statistics, and cross tabulations (each wave)

- Copies of telephone interviews (as audio files; blinded)

- Proprietary question slide deck and frequency tables

- Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions in each wave

Product Coverage:

- Yervoy (ipilimumab), Zelboraf (venurafenib), Temodar, Dacarbazine, Paclitaxel

Companion Reports 2012:

- TreatmentTrends®: CML EU

- TreatmentTrends®: CML US

Related 2011 Reports:

- LaunchTrends®: Zytiga (abiraterone acetate)

- LaunchTrends®: Xalkori (Crizotinib)

- TreatmentTrends®: Multiple Myeloma (US)